{"entity":{"id":"gimema","kind":"company","name":"GIMEMA","aka":["Gruppo Italiano Malattie EMatologiche dell'Adulto","Italian Group for Adult Hematologic Diseases"],"tldr":"Italy's adult haematology trials group, famous for making acute promyelocytic leukaemia curable without chemotherapy and for chemotherapy-free Philadelphia-positive ALL.","summary":"Founded in 1982, GIMEMA coordinates more than 100 Italian haematology centres from Rome. With the German AMLSG it ran APL0406, which showed all-trans retinoic acid plus arsenic trioxide beats chemotherapy in low-to-intermediate risk acute promyelocytic leukaemia, and its LAL2116 D-ALBA trial showed dasatinib followed by blinatumomab can induce deep molecular responses in Ph-positive ALL without cytotoxic chemotherapy. GIMEMA also runs CML, CLL, myeloma and MDS trials and a central laboratory network for molecular monitoring. Its quality-of-life working party pioneered patient-reported outcomes in haematology trials.","asOf":"2026-09-09","links":[{"label":"GIMEMA","url":"https://www.gimema.it"}],"tags":["cooperative-group"],"related":["blinatumomab","imatinib"],"cancers":["aml","all-leukemia","cll","multiple-myeloma"],"sections":[],"technologies":["t-cell-engager","kinase-inhibitors","mrd-testing"],"targets":[],"drugs":[],"companies":["hovon"],"institutions":[],"pathways":[],"terms":["mrd"],"trials":["d-alba"],"people":["marco-vignetti","antonio-cuneo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["APL0406 (ATRA-arsenic in APL)","D-ALBA (chemo-free Ph+ ALL)","CML and CLL trials","Central molecular monitoring laboratories"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Rome","country":"IT","companyType":"cooperative-group","website":"https://www.gimema.it","founded":1982,"investors":[],"funding":[]},"route":"/companies/gimema/","neighbours":{"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"company":[{"id":"hovon","kind":"company","name":"HOVON","route":"/companies/hovon/"}],"term":[{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"trial":[{"id":"apl0406","kind":"trial","name":"APL0406","route":"/trials/apl0406/"},{"id":"cyto-pv","kind":"trial","name":"CYTO-PV","route":"/trials/cyto-pv/"},{"id":"d-alba","kind":"trial","name":"D-ALBA (GIMEMA LAL2116)","route":"/trials/d-alba/"}],"person":[{"id":"antonio-cuneo","kind":"person","name":"Antonio Cuneo","route":"/people/antonio-cuneo/"},{"id":"marco-vignetti","kind":"person","name":"Marco Vignetti","route":"/people/marco-vignetti/"}],"institution":[{"id":"eha","kind":"institution","name":"European Hematology Association","route":"/institutions/eha/"},{"id":"airc","kind":"institution","name":"Fondazione AIRC per la ricerca sul cancro","route":"/institutions/airc/"}]}}